131 related articles for article (PubMed ID: 26462054)
21. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library.
Zhang Q; Liu Y; Gao F; Ding Q; Cho C; Hur W; Jin Y; Uno T; Joazeiro CA; Gray N
J Am Chem Soc; 2006 Feb; 128(7):2182-3. PubMed ID: 16478150
[TBL] [Abstract][Full Text] [Related]
22. Functionalized Silica Nanoparticles As an Alternative Platform for Targeted Drug-Delivery of Water Insoluble Drugs.
de Oliveira LF; Bouchmella K; Gonçalves Kde A; Bettini J; Kobarg J; Cardoso MB
Langmuir; 2016 Apr; 32(13):3217-25. PubMed ID: 26930039
[TBL] [Abstract][Full Text] [Related]
23. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
[TBL] [Abstract][Full Text] [Related]
24. Mesoporous silica nanoparticle facilitated drug release through cascade photosensitizer activation and cleavage of singlet oxygen sensitive linker.
Lee J; Park J; Singha K; Kim WJ
Chem Commun (Camb); 2013 Feb; 49(15):1545-7. PubMed ID: 23325385
[TBL] [Abstract][Full Text] [Related]
25. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
Botella P; Abasolo I; Fernández Y; Muniesa C; Miranda S; Quesada M; Ruiz J; Schwartz S; Corma A
J Control Release; 2011 Dec; 156(2):246-57. PubMed ID: 21756949
[TBL] [Abstract][Full Text] [Related]
26. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
27. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
[TBL] [Abstract][Full Text] [Related]
28. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery.
Zhang J; Yuan ZF; Wang Y; Chen WH; Luo GF; Cheng SX; Zhuo RX; Zhang XZ
J Am Chem Soc; 2013 Apr; 135(13):5068-73. PubMed ID: 23464924
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells.
Tung WL; Hu SH; Liu DM
Acta Biomater; 2011 Jul; 7(7):2873-82. PubMed ID: 21439410
[TBL] [Abstract][Full Text] [Related]
31. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
32. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
33. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery.
Hartono SB; Gu W; Kleitz F; Liu J; He L; Middelberg AP; Yu C; Lu GQ; Qiao SZ
ACS Nano; 2012 Mar; 6(3):2104-17. PubMed ID: 22385282
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
36. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
37. Anisotropic growth-induced synthesis of dual-compartment Janus mesoporous silica nanoparticles for bimodal triggered drugs delivery.
Li X; Zhou L; Wei Y; El-Toni AM; Zhang F; Zhao D
J Am Chem Soc; 2014 Oct; 136(42):15086-92. PubMed ID: 25251874
[TBL] [Abstract][Full Text] [Related]
38. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
39. Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor.
Larroque-Lombard AL; Ning N; Rao S; Lauwagie S; Halaoui R; Coudray L; Huang Y; Jean-Claude BJ
Chem Biol Drug Des; 2012 Dec; 80(6):981-91. PubMed ID: 22943437
[TBL] [Abstract][Full Text] [Related]
40. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
